Verona Pharma expects its new COPD drug to become a valuable addition to drugs commonly used by patients
Verona Pharma revealed the top-line results from its Phase 2a clinical trial, in which RPL554 was dosed in addition to…
Pharmaceuticals, Biotechnology and Life Sciences
Verona Pharma revealed the top-line results from its Phase 2a clinical trial, in which RPL554 was dosed in addition to…
Respiratory diseases biopharmaceutical specialist, Verona Pharma said Tuesday that the U.S. Food and Drug Administration has given the green light for the kick-start of a pharmacokinetic (PK) clinical trial in the U.S. for its RPL554 candidate, with the acceptance of an Investigational New Drug application (IND).
Verona Pharma reports positive results from RPL554 dose-finding study
Verona Pharma has completed patient enrolment for the Phase IIa dose-finding study of RPL554 in asthma and the Phase IIa combination study of RPL554 in chronic obstructive pulmonary disease (COPD), in which the drug is being administered in addition to standard of care bronchodilators.
Verona Pharma plc , the drug development company focused on first-in-class medicines to treat respiratory diseases, has announced that the first patients have been dosed in a Phase IIa combination study to evaluate the addition of RPL554 to standard reliever medications for chronic obstructive pulmonary disease (COPD).